-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $65

Benzinga·10/27/2025 14:19:59
Listen to the news
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $63 to $65.